Furthermore, no matter cut-off value is 30 (cut-off value for predicting biallelic inactivation of BRCA1/2 with our NGS-panel in ovarian cancer) or 42 (Myraid HRD), GI/HRD score was not associated with improved survival of patients with platinum-based chemotherapy (Supplementary Fig. 8b). This evidence concerns the gene BRCA1 and ovarian cancer.